Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2008 Results
Date:2/11/2009

ence call. A telephone replay of the conference call will be available through Thursday, February 19, 2009 by calling 1-800-642-1687 for domestic and +1-706-645-9291 for international. Please use the pass code 84377791 to access the replay.

Forward Looking Statements

This news release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by the fact that words such as "expects", "anticipates", "intends", "estimates", "believes" or similar expressions are used in connection with any discussion of future financial or operating performance. Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed in the Company's periodic reports filed with the U.S. Securities and Exchange Commission. Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation or regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materia
'/>"/>

SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Cambrex To Announce Third Quarter 2007 Financial Results on November 1, 2007
2. Cambrex Signs Agreement To Acquire ProSyntest AS
3. Cambrex Reports Fourth Quarter and Full-Year 2007 Results
4. Cambrex Customer Announced Recall
5. Cambrex to Announce First Quarter 2008 Financial Results on May 1, 2008
6. Cambrex Presentation at The JPMorgan Healthcare Conference to be Webcast
7. Skinvisible and Cambrex Enter Into Agreement to Develop Acne Products
8. Cambrex to Announce Fourth Quarter 2008 Financial Results on February 11, 2009
9. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
10. Haemacure Reports Third Quarter 2007 Results
11. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... entered into an agreement with one of the ... drug candidates for the detection and treatment of ... novel antibody discovery and Roche,s expertise in developing ... possibility of improved treatment for cancer, a leading ... makes use of BTI,s discovery of a new ...
(Date:7/14/2014)... Florida (PRWEB) July 14, 2014 Botanica ... Open House event will be held at the day ... July 16th from 4-8pm. Wine and other refreshments will ... of retail discounts on beauty products and ... treatment known as dermaplaning. , Dermaplaning (also known ...
(Date:7/14/2014)... Barbara Bronson Gray ... (HealthDay News) -- New research suggests that a faltering ... Alzheimer,s disease, and that an inexpensive, low-tech smell test ... In two different studies, the decreased ability to ... cell function and progression to Alzheimer,s disease. "We,re ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, 2014 (HealthDay ... have bigger brains and sharper thinking skills than their peers, ... between playing games such as puzzles, crosswords, cards and checkers ... Researchers found that people who played those games at ... and other mental functions. And, based on MRI scans, they ...
(Date:7/14/2014)... Atlanta, GA (PRWEB) July 14, 2014 ... networking and relationship-marketing firm, announced today that nominations ... for the 2014 Information Security Executive® (ISE®) North ... Security Executive® of the Year, which recognizes executives ... organizations through risk management, data-asset protection, regulatory compliance, ...
Breaking Medicine News(10 mins):Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 2Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 3
... liver disease (NAFLD) is the most common cause of ... for patients with NAFLD is currently available//. Understanding the ... patients with NAFLD is important for patient counseling as ... ,To deal with these issues, researchers from Mayo Clinic ...
... genetically modified mosquito has been created that wipe out natural ... of the world such as India and South Asia. ... the wild in an attempt to combat malaria that is ... ,A similar attempt was made in India in 1970s ...
... to start its Phase III cancer vaccine trial against ... is the new skin cancer vaccine developed by Antigenics.// ... 322 patients failed to meet the required statistically significance ... was not shown to have any better results compared ...
... news for adults with acne and resultant facial scarring. ... Surgery, the medical journal of the American Society for ... - or non-ablative - lasers showed significant improvement of ... common with ablative procedures, such as facial resurfacing, dermabrasion ...
... survival rate of women with breast cancer has increased by ... years//. The experts feel that the increase in breast cancer ... detection of breast cancer and also due to more effective ... of cancer. ,Professor Michel Coleman, Epidemiologist, Cancer Research ...
... found that it is better to insert drug-coated stents ... who have diabetes//. ,The study author Dr. ... University Hospital in Madrid said that the results of ... have poorer prognosis as compared to non-diabetics after angioplasty. ...
Cached Medicine News:Health News:Weight reduction by 5% may help in treating nonalcoholic fatty liver disease 2Health News:Breast cancer women has shown an increase in survival rates 2
(Date:7/14/2014)... Lumin Medical LLC, a healthcare IT provider, ... leading provider of on-demand patient tracking solutions and is ... to Franklin, Wis. ... and our mission is to provide visibility for the ... reduce costs," said James Hermann , President of ...
(Date:7/14/2014)... DIEGO , July 14, 2014  More than any ... their smartphones and tablet computers -- but their eyes don,t. ... have never needed before, and the eye has not evolved ... and what our eyes can do comfortably often results in ... collectively known as Digital Eye Strain. Now ZEISS has invented ...
(Date:7/14/2014)... EAGAN, Minn. , July 14, 2014  Today, ... Partners, announced that it acquired the assets of MicroTest ... MA.  The acquisition of MTL is the first step ... and chemistry laboratory services platform to support the medical ... be known as Accuratus Lab Services , a ...
Breaking Medicine Technology:Lumin Medical Purchases PatientTrak 2Lumin Medical Purchases PatientTrak 3New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3
... III Study for the Treatment of Advanced Prostate CancerPARSIPPANY, ... launch of a Phase IIIB clinical trial of degarelix ... antagonist approved by the U.S. Food and Drug Administration ... cancer. The announcement was made at ...
... Diagnostic ToolSUNNYVALE, Calif., April 27 Cepheid (Nasdaq: ... MTB/RIF as a CE IVD Mark product under the ... Devices. For the first time, European clinicians will have ... Mycobacterium tuberculosis (MTB) and resistance to rifampicin ...
Cached Medicine Technology:Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 2Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 3Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 4Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6
... a low osmolar ionic dimer. Each ... meglumine, 196 mg of ioxaglate sodium ... disodium as a stabilizer. The solution ... each milliliter and provides 32% (320 ...
... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
... is a liver-specific contrast agent approved for ... Its introduction expands the Amersham Health portfolio ... injected intravenously, TESLASCAN aids in the detection, ... Imaging can begin within minutes of injection, ...
... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
Medicine Products: